Skip to content

US · KROS · BIOTECHNOLOGY

Keros Therapeutics, Inc. (KROS) intrinsic value and stock valuation

$11.08as of 2026-11-21 · Mkt cap 319.82M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Keros Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values KROS with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from KROS’s statements →

Keros Therapeutics, Inc. Graham Number

Graham Number: $20.70d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Biotechnology Lexington, MA 02421 kerostx.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$244.1M
20182025
Net income
$87M
20182025
Free cash flow
$106M
20182025
Total equity
$303.1M+3% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$244.1M$3.55M$150K$0.00$20.1M
Operating income$70.6M-$-210.83M-$-169.94M-$-114.79M-$-56.37M
Net income$87M-$-187.35M-$-152.99M-$-104.68M-$-58.74M
EPSd$2.3M-$-5M-$-5.19M-$-4.15M-$-2.52M
Operating cash flow$107.5M-$-160.87M-$-124.51M-$-70.06M-$-62.15M
Capital expenditure-$-1.55M-$-1.93M-$-2.46M-$-1.24M-$-1.02M
Free cash flow$106M-$-162.8M-$-126.97M-$-71.3M-$-63.17M
Total assets$338M$615.9M$370M$306.8M$255.3M
Total debt$16.9M$18.9M$14.4M$13.3M$1.09M
Net debt-$-270.53M-$-541.07M-$-316.7M-$-265.78M-$-228.95M
Total equity$303.1M$571.6M$332.2M$277.4M$243.2M
Cash and short-term investments$287.4M$559.9M$331.2M$279.1M$230M
Income statement
20252024202320222021
Revenue$244.1M$3.55M$150K$0.00$20.1M
Cost of revenue$1.51M$0.00$0.00$0.00$0.00
Gross profit$242.6M$3.55M$150K$0.00$20.1M
Research and development expenses$129.6M$173.6M$135.3M$87.3M$55.1M
Selling, general and administrative expenses$46.9M$40.8M$34.8M$27.5M$21.3M
Other expenses-$-4.56M$0.00$0.00$0.00$0.00
Operating expenses$171.9M$214.4M$170.1M$114.8M$76.5M
Cost and expenses$173.4M$214.4M$170.1M$114.8M$76.5M
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$1.51M$1.23M$810K$670K$380K
Ebitda$93.4M-$-185.82M-$-152.18M-$-104M-$-56.35M
Operating income$70.6M-$-210.83M-$-169.94M-$-114.79M-$-56.37M
Total other income/expenses, net$21.3M$23.8M$17M$10.1M-$-360K
Income before tax$91.9M-$-187.05M-$-152.99M-$-104.68M-$-56.73M
Income tax expense$4.88M$300K$0.00$0.00$2.01M
Net income$87M-$-187.35M-$-152.99M-$-104.68M-$-58.74M
Weighted average shares outstanding$37.2M$37.4M$29.5M$25.2M$23.3M
Weighted average diluted shares outstanding$37.9M$37.4M$29.5M$25.2M$23.3M
Balance sheet
20252024202320222021
Cash and short-term investments$287.4M$559.9M$331.2M$279.1M$230M
Net receivables$6.37M$4.46M$1.09M$840K$18.2M
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$315.4M$588.9M$347.3M$285.8M$251.4M
Property, plant and equipment, net$21.1M$23.5M$19.5M$17.6M$2.4M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$1.45M$1.45M$1.21M$0.00$0.00
Total non-current assets$22.6M$27M$22.7M$21M$3.81M
Total assets$338M$615.9M$370M$306.8M$255.3M
Accounts payable$1.97M$4.6M$5.45M$3.34M$3.65M
Short-term debt$2.41M$1.98M$1M$460K$860K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$20.4M$27.5M$24.4M$16.6M$11.9M
Long-term debt$14.5M$16.9M$13.4M$12.8M$230K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$14.5M$16.9M$13.4M$12.8M$230K
Capital lease obligations$16.9M$18.9M$14.4M$13.3M$1.09M
Total liabilities$34.9M$44.3M$37.8M$29.4M$12.1M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-481.76M-$-568.78M-$-381.43M-$-228.43M-$-123.75M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$303.1M$571.6M$332.2M$277.4M$243.2M
Total investments$1.45M$1.45M$1.21M$0.00$0.00
Total debt$16.9M$18.9M$14.4M$13.3M$1.09M
Net debt-$-270.53M-$-541.07M-$-316.7M-$-265.78M-$-228.95M
Cash flow statement
20252024202320222021
Net income$87M-$-187.35M-$-152.99M-$-104.68M-$-58.74M
Depreciation and amortization$1.51M$1.23M$810K$670K$380K
Stock-based compensation$28.7M$34.9M$28.8M$18.7M$11.7M
Change in working capital-$-12.11M-$-11.44M-$-2.65M$14.3M-$-16.07M
Accounts receivable-$-820K-$-2.6M-$-140K$18M-$-18M
Inventory$0.00$0.00-$-4.5M$0.00$1.04M
Accounts payable-$-3M-$-250K$1.61M-$-410K$1.49M
Net cash provided by operating activities$107.5M-$-160.87M-$-124.51M-$-70.06M-$-62.15M
Investments in property, plant and equipment-$-1.55M-$-1.93M-$-2.46M-$-1.24M-$-1.02M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-1.55M-$-1.93M-$-2.46M-$-1.24M-$-1.02M
Common stock issued-$-3.47M$380.1M$175.8M$119.6M$28.2M
Common stock repurchased-$-375M$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-378.47M$391.8M$179M$120.3M$28.6M
Net change in cash-$-272.52M$229M$52M$49M-$-34.62M
Cash at end of period$288.9M$561.4M$332.4M$280.4M$231.4M
Operating cash flow$107.5M-$-160.87M-$-124.51M-$-70.06M-$-62.15M
Capital expenditure-$-1.55M-$-1.93M-$-2.46M-$-1.24M-$-1.02M
Free cash flow$106M-$-162.8M-$-126.97M-$-71.3M-$-63.17M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Keros Therapeutics, Inc.

        Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.

        CEO
        Jasbir S. Seehra
        Employees
        78
        Beta
        0.97

        Explore

        Frequently asked questions

        What is the intrinsic value of Keros Therapeutics, Inc. (KROS)?

        InvestorsCraft does not currently publish an intrinsic value for KROS. How the IC value is calculated.

        Is KROS undervalued?

        InvestorsCraft does not publish an undervaluation signal for KROS at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.